医学
斯科普斯
糖尿病
结直肠癌
内科学
入射(几何)
科学网
癌症
家庭医学
梅德林
肿瘤科
荟萃分析
内分泌学
物理
光学
法学
政治学
作者
Raymond Ngai Chiu Chan,Robert Chan,Oscar Hou-In Chou,Gary Tse,Sharen Lee
标识
DOI:10.1016/j.ejim.2023.01.021
摘要
Diabetes mellitus is a global public health issue affecting 536.6 million people worldwide in 2021 [ [1] Sun H. Saeedi P. Karuranga S. Pinkepank M. Ogurtsova K. Duncan B.B. et al. IDF Diabetes Atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract. 2022; 183 (Epub 20211206PubMed PMID: 34879977)109119https://doi.org/10.1016/j.diabres.2021.109119 Abstract Full Text Full Text PDF Scopus (664) Google Scholar ]. Previous studies have established clear epidemiological links between diabetes mellitus and various co-morbidities, including colorectal cancers (CRC) [ 2 Giovannucci E. Harlan D.M. Archer M.C. Bergenstal R.M. Gapstur S.M. Habel L.A. et al. Diabetes and cancer: a consensus report. Diabetes Care. 2010; 33: 1674-1685https://doi.org/10.2337/dc10-0666 Crossref PubMed Scopus (1390) Google Scholar , 3 Vigneri P. Frasca F. Sciacca L. Pandini G. Vigneri R. Diabetes and cancer. Endocr Relat Cancer. 2009; 16 (Epub 20090720PubMed PMID: 19620249): 1103-1123https://doi.org/10.1677/ERC-09-0087 Crossref PubMed Scopus (795) Google Scholar , 4 De Bruijn K.M. Arends L.R. Hansen B.E. Leeflang S. Ruiter R. van Eijck C.H. Systematic review and meta-analysis of the association between diabetes mellitus and incidence and mortality in breast and colorectal cancer. Br J Surg. 2013; 100 (PubMed PMID: 24037561): 1421-1429https://doi.org/10.1002/bjs.9229 Crossref PubMed Scopus (151) Google Scholar ]. Several groups investigated the effects of anti-diabetic medications on the risk of CRC. However, the effects of newer agents, especially dipeptidyl peptidase 4 inhibitors (DPP4i) and sodium-glucose co-transporter 2 inhibitors (SGLT2i), received less attention. To compare the risks of incident CRC amongst DPP4i and SGLT2i users, we conducted the present study using a large territory wide cohort in Hong Kong consisting of all type 2 diabetes mellitus (T2DM) patients on any of the two medication classes.
科研通智能强力驱动
Strongly Powered by AbleSci AI